Sertraline is a selective serotonin reuptake inhibitor used as an antidepressant and antipanic agent in children and adolescents. Sertraline is well tolerated and its safety profile in overdose is favorable. However, sertraline overdose may cause a toxic hyperserotonergic state known as serotonin syndrome (SS). Serotonin syndrome may be misdiagnosed in children because it has been reported mostly in adults. In the present case report, we describe a 16-year-old female patient who ingested 2000 mg of sertraline to attempt suicide. The patient showed symptoms and signs suggestive of SS, characterized by an asynchronicity between organic and psychiatric symptoms. In addition, the patient showed a variability of psychiatric symptoms through time. Thirteen hours after sertraline overdose, she was poorly cooperative with poverty of speech and marked emotional tension, but she was oriented in space and time and was able to remember what happened to her and to reconstruct the dynamics of the fact. Twenty-four hours after sertraline overdose, the patient developed a delusion of reference associated with intense anxiety and depressed mood. In the present case report, we discuss the pathophysiologic mechanisms of the observed clinical manifestations and propose an observation period for sertraline overdose in children and adolescents that is sufficiently long (at least 72 hours) even in the absence of unstable vital signs.
S ertraline is a selective inhibitor of serotonin reuptake into presynaptic terminals. 1, 2 As with other selective serotonin reuptake inhibitors (SSRIs), sertraline is an antidepressant and antipanic agent that reduces the firing of neurons in the raphe nucleus, which in turn can affect the noradrenergic neurons of the locus coeruleus. 3 Sertraline has a linear pharmacokinetic profile (ie, its plasmatic concentration is proportional to the dose administered) and a half-life of approximately 26 hours. 4 Many clinical trials have demonstrated the efficacy of sertraline in depressive disorders as compared with both placebo and other antidepressant drugs. Its efficacy has been demonstrated in randomized and controlled trials of patients with obsessive-compulsive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder. 4 The literature suggests that sertraline is a well-tolerated and safe antidepressant when compared with other SSRIs or tricyclic antidepressants. 5 The typical adverse effects of sertraline include gastrointestinal symptoms (ie, nausea, dyspepsia, and diarrhea), central nervous system effects (ie, somnolence or insomnia), and other symptoms such as tremor, dry mouth, and dizziness as well as treatment-induced sexual dysfunction. Moreover, withdrawal reactions may be associated with the abrupt discontinuation of the agent. 4 There is evidence that the pharmacokinetic and safety properties of sertraline in children and adolescents are similar to those reported for adults. 6 The safety profile of sertraline in overdose is very favorable. 4 However, sertraline overdose causes a toxic hyperserotonergic state known as serotonin syndrome (SS), which is often described as a clinical triad of mental status changes, neuromuscular abnormalities, and autonomic dysfunction, although these symptoms may not be present in the same patient at the same time. [7] [8] [9] In the past years, the use of SSRIs has increased among children and adolescents, 10 and the incidence of SS precisely reflects the increased number of serotonergic agents used in pediatric population. 7 Serotonin syndrome has an estimated incidence of 14% to 16% of people who overdose on SSRIs. 11 Although severe cases have been reported with an overdose of a single agent, they more often occur with a combination of 2 or more serotonergic agents even if they are used at therapeutic doses. 12 Serotonin syndrome in children may be misdiagnosed because it has been reported mostly in adults. However, given the increased incidence of SS in children, it is important to recognize early its clinical manifestations. 7 
CASE PRESENTATION
A 16-year-old female patient was referred to our emergency department (ED) because of an intentional sertraline overdose. The patient was admitted after she had voluntarily taken 20 pills of 100 mg sertraline (2000 mg) 13 hours before admission. When the patient arrived at the hospital, she was poorly cooperative with poverty of speech and marked emotional tension. Physical examination showed mydriasis, nystagmus, and hand and leg tremors, but not any other neurological deficit. The patient also complained of nausea and gastric pain. The white blood cell count was 18 Â 10 3 /μL with 8.1% neutrophils and 4.3% lymphocytes. She had hyperglycemia (139 mg/dL; normal range, 65-100 mg/dL), normal renal and hepatic function with blood urea nitrogen level of 21 mg/dL, creatinine level of 0.79 mg/dL, alanine aminotransferase level of 20 U/L, and aspartate aminotransferase level of 16 U/L. Creatine kinase level was normal. Vital signs included heart rate of 150 beats per minute, blood pressure of 130/60 mm Hg, eupnea with peripheral oxygen saturation (SaO 2 ) of 97%, and Glasgow Coma Scale score of 15. A peripheral intravenous line was established, and she was given fluids (0.9% sodium chloride). Fifteen minutes after ED admission, the patient was also treated with activated charcoal (15 gr) and was admitted to the observation unit for continuous monitoring of vital signs. Psychiatric examination revealed that the patient was oriented in space and time, had coherent speech, and was able to remember what had actually happened and to reconstruct the dynamics of the fact. The patient reported that she was experiencing an eating disorder (anorexia alternating with bulimia) and recurrent hypomanic and dysthymic episodes lasting approximately 2 years. For this reason, the patient was undertaking psychotherapy, which had started a few weeks before entering the ED. Twenty-four hours after ED admission, the patient developed a delusion of reference associated with intense anxiety and depressed mood. The patient was sure that others were talking about her and pointed at her. The delusional content was focused on sex identity. She was not able to sleep. The patient was carefully monitored: vital signs were stable, white blood cell count was 11 Â 10 3 /μL with normal neutrophil range, and blood glucose level was normal (83 mg/dL). Fortyeight hours after ED admission, the patient still showed anxiety, ideas of reference, depressed mood, and suicidal ideation, but the symptoms were less intense than before. Vital signs were stable and the neurological examination result was normal. She was prescribed 0.5 mg of risperidone and 1 mg of lorazepam. However, the therapy was not administered because most of the symptoms resolved spontaneously within 50 hours of ED admission. Subsequently, the patient was transferred to the pediatric ED because of the need for further clinical evaluation and a more targeted therapy. In the Table 1 , the progress of the symptoms is summarized.
DISCUSSION
This case report describes a 16-year-old female patient who presented to the ED after taking 2000 mg of sertraline to attempt suicide, with symptoms suggestive of SS such as autonomic instability, delirium, and tremors. Serotonin syndrome is a predictable consequence of overstimulation of the serotonin receptors, although the exact pathophysiology is not very well known. 9 Serotonin syndrome is characterized by a triad of mental, autonomic, and neurological symptoms that usually begin suddenly in less than 24 hours after the beginning of treatment or overdose. 7, 9, [13] [14] [15] Mild cases present with mydriasis, diaphoresis, tachycardia, tremor, clonus, and hyperreflexia, typically more prominent in the lower extremities. 13, 14 Moderate cases may also present gastrointestinal symptoms, fever, and rhabdomyolysis. Neurological symptoms such as altered mental status, insomnia, and agitation are also common. 13 Severe cases may present with profound hypertension and tachycardia, high fever, seizures, and delirium and may evolve into coma. 14 The management of patients with SS relies on early recognition, removal of the precipitating drugs, and supportive care including external cooling, antihypertensive drugs, muscular paralysis, and sedation. 9, 14, 15 Treatment includes standard gastric decontamination with lavage or activated charcoal for most patients. 16 For their nonspecific inhibitory effects on serotonergic transmission, benzodiazepines (BDZ) are the most important drugs in the management of most cases. 9, 15 Severe cases with hyperthermia should receive supportive care, BDZ, and immediate sedation with neuromuscular paralysis. 7 The control of hyperthermia should be attempted with BDZ and muscular paralysis induced by nondepolarizing agents such as vecuronium followed by mechanical ventilation. There is no rule for antipyretic agents because the hyperthermia is caused by excessive muscular activity and not hypothalamic dysfunction. Hypertension and tachycardia should be treated with short-acting agents such as nitroprusside. 7 Propranolol should be avoided because it might cause shock in patients with autonomic instability. For its nonspecific antagonism properties at 5-HT1 and 5-HT2 receptors, cyproheptadine is another important drug for the management of SS, especially in mild to moderate cases, with no adverse effects. It is available only as an oral preparation, and the recommended pediatric dosage is 0.25 mg/kg/d, every 2 hours until symptoms improvement. 7, 8, 15 In the present case we describe an asynchronicity between organic and psychic symptoms. In fact, in the early hours after sertraline overdose, the patient developed tachycardia, hypertension, and neurological symptoms. Delusion and other psychiatric symptoms occurred approximately 37 hours after sertraline overdose when the inhibitory action of serotonin on dopamine was reduced. In addition, the patient showed a variability of psychiatric symptoms through time: at first she was anxious but oriented in space and time and able to remember what had happened to her and to reconstruct the dynamics of the fact; subsequently, the patient developed a delusion of reference associated with intense anxiety and depressed mood. Serotonin acts primarily as a modulator of other neurotransmitter systems including the dopaminergic system. Serotonergic neurons of the dorsal and median raphe nuclei innervate the dopaminergic neurons of the substantia nigra and the ventral tegmental area and interact with the synaptic terminals of dopaminergic neurons in the striatum, nucleus accumbens, and medial prefrontal cortex. The serotonergic activity of these neurons decreases dopamine transmission and modulates the activity of these pathways. 15 The variation of serotonin activity in neural networks described previously may explain the pathophysiological mechanisms underlying the timing of the presentation of psychiatric symptoms in the patient. Based on 
